Literature DB >> 10564135

Contribution of the Na(+) channel and Na(+)/H(+) exchanger to the anoxic rise of [Na(+)] in ventricular myocytes.

B N Eigel1, R W Hadley.   

Abstract

The aim of this study was to quantify the contribution of the Na(+)/H(+) exchanger (NHE) and the Na(+) channel to the rise in cytosolic Na(+) concentration ([Na(+)]) that is seen in anoxic guinea pig ventricular myocytes. [Na(+)] was measured with the use of microfluorometry and was found to rise to 44 mM after prolonged anoxia. This rise was partially sensitive to either TTX or HOE-642, selective inhibitors of the Na(+) channel and NHE1, respectively. [Na(+)] did not significantly rise when both drugs were present, suggesting that other routes of Na(+) entry were insignificant. However, the relative contributions of the NHE and the Na(+) channel were found to be remarkably sensitive to ionic conditions expected to occur during ischemia. The Na(+) channel was the dominant Na(+) source during acidic anoxia. However, the NHE was the dominant Na(+) source during both hyperkalemic anoxia and simulated ischemia (hyperkalemia, low pH, and anoxia). The data suggest that the NHE may prove to be the best pharmacological target to reduce Na(+) entry during true ischemia and that inhibition of Na(+) influx could contribute strongly to the cardioprotective effects of NHE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10564135     DOI: 10.1152/ajpheart.1999.277.5.H1817

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  Persistent (current) in the face of adversity ... a new class of cardiac anti-ischaemic compounds on the horizon?

Authors:  David A Saint
Journal:  Br J Pharmacol       Date:  2009-01-07       Impact factor: 8.739

2.  Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current.

Authors:  S Weiss; D Benoist; E White; W Teng; D A Saint
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine.

Authors:  L Belardinelli; J C Shryock; H Fraser
Journal:  Heart       Date:  2006-07       Impact factor: 5.994

4.  p21-Activated kinase1 (Pak1) is a negative regulator of NADPH-oxidase 2 in ventricular myocytes.

Authors:  Jaime DeSantiago; Dan J Bare; Lei Xiao; Yunbo Ke; R John Solaro; Kathrin Banach
Journal:  J Mol Cell Cardiol       Date:  2013-12-28       Impact factor: 5.000

Review 5.  The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure.

Authors:  M Karmazyn; J V Sostaric; X T Gan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Pathophysiology of the cardiac late Na current and its potential as a drug target.

Authors:  Jonathan D Moreno; Colleen E Clancy
Journal:  J Mol Cell Cardiol       Date:  2011-12-16       Impact factor: 5.000

7.  Combined blockade of the Na+ channel and the Na+/H+ exchanger virtually prevents ischemic Na+ overload in rat hearts.

Authors:  Michiel ten Hove; Maurits A Jansen; Marcel G J Nederhoff; Cees J A Van Echteld
Journal:  Mol Cell Biochem       Date:  2006-11-11       Impact factor: 3.396

Review 8.  The cardiac persistent sodium current: an appealing therapeutic target?

Authors:  D A Saint
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

9.  Does enhanced expression of the Na+-Ca2+ exchanger increase myocardial vulnerability to ischemia/reperfusion injury in rabbit hearts?

Authors:  Tomoaki Matsumoto; Tetsuji Miura; Takayuki Miki; Yasuhiro Nishino; Yuichi Nakamura; Kazuaki Shimamoto
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

10.  Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.

Authors:  Jonathan D Moreno; Pei-Chi Yang; John R Bankston; Eleonora Grandi; Donald M Bers; Robert S Kass; Colleen E Clancy
Journal:  Circ Res       Date:  2013-07-29       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.